Sanofi turns to an up­start in the mR­NA field in lat­est at­tempt to quick­ly squelch a glob­al pan­dem­ic

6 years ago
R&D
Coronavirus

Ver­tex joins Mer­ck, Pfiz­er — re­vamp­ing multi­bil­lion-dol­lar tri­al strat­e­gy as biotech R&D crum­bles

6 years ago
R&D
Coronavirus

Pfiz­er, My­lan deal takes a coro­n­avirus hit

6 years ago
Deals
Coronavirus

Take­da antes up $44M for rare dis­ease pact, turn­ing to Ox­ford spin­out's ex­o­some tech

6 years ago
Deals

EMA of­fers method­olog­i­cal con­sid­er­a­tions for tri­als dur­ing Covid-19 pan­dem­ic

6 years ago
FDA+
Coronavirus

Kept on hold at the FDA, Ipsen scraps a key tri­al and re­vamps R&D path for its trou­bled $1B-plus rare dis­ease drug

6 years ago
R&D
FDA+

Cou­pling mR­NA with tR­NA and new de­liv­ery tech, MPM and Or­biMed help birth new $80M biotech in­to a slowed down world

6 years ago
Financing
Startups

SutroVax lands an­oth­er $100M+ in up­start quest against Pfiz­er’s block­buster Pre­vnar 13

6 years ago
Financing

Covid-19 roundup: In­ter­cept, blue­bird and a grow­ing list of biotechs feel the pain as pan­dem­ic man­gles FDA, R&D ...

6 years ago
Coronavirus

Bris­tol My­ers bags a long-await­ed FDA OK for ozan­i­mod — but the pan­dem­ic will keep it off the mar­ket

6 years ago
Pharma
FDA+

Af­ter crit­ics lam­bast­ed Gilead for grab­bing the FDA's spe­cial rare drug sta­tus on remde­sivir, they're giv­ing it back

6 years ago
Pharma
FDA+

Roche forges deal with San Diego biotech, bet­ting on new an­tibi­ot­ic class

6 years ago
Deals

Oprah day in biotech: Re­ge­na­cy gets $30M, Ab­bisko gets $70M, Cas­tle Creek gets $75M

6 years ago
News Briefing

Covid-19 roundup: Bris­tol My­ers sus­pends clin­i­cal tri­als, grounds field team; Vir ush­ers an­ti­body can­di­dates to hu­man ...

6 years ago
Coronavirus

In two-way race with No­var­tis, Mer­ck scores first reg­u­la­to­ry ap­proval for tar­get­ed lung can­cer drug

6 years ago
R&D

FDA is­sues an­oth­er safe­ty alert re­lat­ed to fe­cal trans­plants, as da­ta sug­gest coro­n­avirus lingers in poop

6 years ago
FDA+
Coronavirus

BeiGene scram­bles to find new Abrax­ane sup­pli­er as Chi­nese in­spec­tors or­der halt on im­ports, cit­ing Bris­tol My­ers ...

6 years ago
China
FDA+

The first big hur­dle on the Cel­gene CVR ar­rives to­day. Can Bris­tol My­ers clear a low bar in the mid­dle of a pan­dem­ic?

6 years ago
FDA+

Mod­er­na CEO Stéphane Ban­cel out­lines a short path for emer­gency use of a coro­n­avirus vac­cine

6 years ago
Coronavirus

Kally­ope lands $112 mil­lion Se­ries C to ride the gut-brain ax­is for an­oth­er 3 years

6 years ago
Financing

Join­ing No­var­tis in siR­NA space, As­traZeneca hands Si­lence $80M up­front for dis­cov­ery deal

6 years ago
Deals
Discovery

Turn on, tune in: New York biotech scores $15M+ in chemo­ge­net­ics bet

6 years ago
Startups
Cell/Gene Tx

FDA opens door to emer­gency use of con­va­les­cent plas­ma from re­cov­ered Covid-19 pa­tients

6 years ago
Coronavirus

No­var­tis an­nounces pos­i­tive da­ta from halt­ed Zol­gens­ma tri­al

6 years ago
R&D
First page Previous page 856857858859860861862 Next page Last page
A service from the Financial Times